Phase 3 Study Safety, Tolerability, and Efficacy of ALK-001 on the Progression of Stargardt Disease

  • Research type

    Research Study

  • Full title

    A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

  • IRAS ID

    1014003

  • Contact name

    Alkeus Pharmaceuticals, Inc Alkeus Pharmaceuticals, Inc

  • Contact email

    Trials@alkeuspharma.com

  • Sponsor organisation

    Alkeus Pharmaceuticals, Inc

  • Clinicaltrials.gov Identifier

    NCT07419334

  • Research summary

    The main purpose of this study is to compare the effects on visual acuity of ALK-001 with placebo to find out if ALK-001 is effective for treating participants who have been diagnosed with Stargardt disease (STGD). The study will also measure the amount of ALK-001 in participants blood at various times. This study also intends to learn about the safety and efficacy of ALK-001 in participants with STGD.
    This will be a randomized, “double-masked” study, which means the participants and study staff will not know what treatments the participants receive. Participants will be randomised in a 1:1 ratio to receive either 14 mg ALK-001 or a placebo, which looks like a treatment but does not have any medicine in it. Participants will receive this treatment daily over the course of about 24 months.
    Participants are expected to be in this study for up to about 2 years and 3 months. During this time, they have to go at the study site for study visits (on Day 1, Week 4, Week 12, Month 6 and then every 6 months during the 2-year treatment period, and then a safety follow-up visit 30 days after the end of taking the study medicine) for a total of 9 times.
    In between these study site visits, participants will be contacted by phone weekly for the first 11 weeks, and then monthly until the end of the study.
    Approximately 230 eligible participants will take part in the study at approximately 55 study sites in 11 countries.

  • REC name

    South Central - Hampshire A Research Ethics Committee

  • REC reference

    26/SC/0196

  • Date of REC Opinion

    7 Aug 2026

  • REC opinion

    Further Information Favourable Opinion